All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1500+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Eli Lilly removes BMI from weight loss drug labels, providing additional leeway to prescribing physicians
GLP-1, obesity - Read more [Paywall]

THE GOOD
Business Development

Coherus Biosciences sells Udenyca (targeting TIGIT; Neulasta biosimilar, Amgen) franchise to Intas Pharmaceuticals
Recombinant human granulocyte colony-stimulating factor, cancer - Read more

Ipsen buys global licensing rights to Biomunex Pharmaceuticals’ bispecific BMX-502 (mucosal-associated invariant T cell activating)
Bispecific antibody, cancer - Read more

Takeda buys ex-China rights to Keros Therapeutics’ elritercept (activin inhibitor)
Monoclonal antibody, anemia associated with myelodysplastic syndromes and myelofibrosis, cancer - Read more

Gilead pays $20M for an option for yet-to-be discovered solid tumor ADC (topoisomerase I inhibitor-based) from Tubulis
Antibody-drug conjugate, solid tumor, cancer - Read more

Elevar Therapeutics buys global licensing rights to Relay Therapeutics’ lirafugratinib (fibroblast growth factor receptor 2 inhibitor)
Small molecule, cholangiocarcinoma, solid tumor, cancer - Read more

BridgeBio exercises option to license Unnatural Products’ discovered macrocyclic peptide
Peptide, rare disease, cancer - Read more

CSL Seqirus lands bird flu vaccine supply deal with UK
Vaccine, bird flu (H5N1), pandemic preparedness - Read more

PRESENTED BY YOU?
Get the attention of 1500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Janux Therapeutics’ positive Ph1b dose escalation data of JANX007 T-cell engager (PSMA, CD3, albumin binding) launches stock 50%
Trispecific antibody, prostate cancer - Read more

InventisBio touts positive Ph2 data for D-2570 (TYK2 Inhibitor) in plaque psoriasis
Small molecule, plaque psoriasis - Read more

Cartesian Therapeutics showcases positive updated Ph2 data for Descartes-08 (targeting BCMA) in generalized myasthenia gravis
Cell therapy, generalized myasthenia gravis, mRNA CAR-T - Read more

Revolution Medicines provides updates on its RAS(ON) inhibitor portfolio
Small molecule, pancreatic ductal adenocarcinoma, lung cancer, colorectal cancer - Read more

Tern Pharmaceuticals touts early positive Ph1 data for TERN-701 (BCR-ABL inhibitor) in myeloid leukemia
Small molecule, myeloid leukemia, cancer - Read more

THE GOOD
Fundraises

Revolution Medicines $750M public offering
Small molecule, pancreatic ductal adenocarcinoma, lung cancer, colorectal cancer - Read more

Maze Therapeutics $115M Series D
Small molecule, kidney disease, focal segmental glomerulosclerosis, phenylketonuria - Read more

Orakl Oncology €11M ($11.5M) Seed raise, AI-powered drug development platform
Drug development, techbio, AI - Read more

Orikine Bio €800k ($839k) research funding grant
Bi-specific antibody, autoimmune disease, inflammatory disease - Read more

THE GOOD
Investments

Reckitt plans Mucinex production site expansion to the tune of $200M
Consumer health, cold & flu, over-the-counter - Read more

THE GOOD
Lawsuits

Kiromic BioPharma and SEC reach settlement in clinical hold disclosure trial
Cell therapy, solid tumor, cancer, gamma delta T-cell, allogeneic - Read more

THE GOOD
Mergers & Acquisitions

GE Healthcare to fully acquire Nihon Medi-Physics by buying remaining 50% stake from co-owner Sumitomo Chemical
Radiopharm, radiodiagnostics, molecular imaging agents - Read more

THE GOOD
Partnerships

Bristol Myers Squibb, AI Proteins AI-powered miniprotein drug discovery and development pact, undisclosed targets
Biologics, miniprotein, AI - Read more

Genentech, Cour Pharmaceuticals sign strategic collab for tolerogenic nanoparticle development in autoimmune diseases
Tolerogenic nanoparticle, autoimmune - Read more

Ono Pharmaceutical, Congruence Therapeutics small molecule correctors drug discovery partnership focused on oncology
Small molecule, cancer, drug discovery - Read more

Aptose Biosciences, National Cancer Institute sign R&D partnership focused on tuspetinib (FLT3 inhibitor) in myeloid leukemia and myelodysplastic syndrome
Small molecule, myeloid leukemia, myelodysplastic syndrome, cancer, research & development - Read more

Celltrion, BioMe microbiome-targeting drug development collab
Microbiome-based live biotherapeutic, multidrug-resistant bacterial infection - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

GSK’s hepatitis B therapeutic vaccine hopeful misses Ph1/2 efficacy endpoint, trial terminated
Vaccine, hepatitis B, liver disease - Read more

Kinevant Sciences’ namilumab (anti-GM-CSF) fails in pulmonary sarcoidosis Ph2
Monoclonal antibody, pulmonary sarcoidosis - Read more

Trevi Therapeutics’ human abuse potential study for Haduvio (Nalbuphine opioid analgesic extended release formulation) in chronic cough disappoints investor despite demonstrating statistically significant lower 'drug liking'
Small molecule, chronic cough - Read more

THE BAD
Patient Access

American Diabetes Association warns against using compound versions of popular weight-loss meds
GLP-1, obesity, diabetes, compounding - Read more

THE BAD
Politics & Policy

Pfizer, Eli Lilly push back (and avoid answering detailed questions) on government scrutiny aimed at their telehealth platforms and potential “anti-kickback statute” violations
Telehealth, direct-to-consumer, kickbacks - Read more

THE BAD
Strategic Plans

Orexo ditches GAIA-partnered depression treating app
Virtual health, depression, prescription app - Read more [Paywall]

THE UGLY
Politics & Policy

RFK Jr. made $20k a week (total $326k) from his anti-vax non-profit Children’s Health Defense prior to his presidential run
Anti-vaccine, conspiracy theory - Read more

THE UGLY
Warnings Letters, Form 483s

Applied Therapeutics handed FDA warning letter (in addition to last week’s CRL) regarding govorestat (aldose reductase inhibitor) clinical trial conduct
Small molecule, classic galactosemia - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here